SLDB — Solid Biosciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1707502 ·
Last close
$9.16
Market Cap
$982.18M
52W High
$11.45
52W Low
$6.34
ADV30
955,649
Next earnings
2026-11-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -57,384,000 | -54,799,000 | 420,580,000 | 159,394,000 | 46,505,000 |
| Mar 2026 | 0 | — | -57,308,000 | -56,737,000 | 422,893,000 | 297,099,000 | 48,761,000 |
| Dec 2025 | 0 | — | -49,403,000 | -49,787,000 | 232,540,000 | 59,900,000 | 52,530,000 |
| Sep 2025 | 0 | — | -48,058,000 | -45,776,000 | 273,914,000 | 61,364,000 | 55,966,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-186,844,000
Investing CF
$-87,090,000
Financing CF
$293,817,000
CapEx
$-965,000
Dividends Paid
—
Buybacks
$-13,644,000
EPS Diluted TTM
$-1.80
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,069,311,000
Inventory
—
Receivables
—
ST Investments
$218,284,000
EBIT TTM
$-208,997,000
Pretax Income TTM
$-207,099,000
Interest Exp TTM
$128,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -179,206,000 | -174,325,000 | 232,540,000 | 52,530,000 | — | -156,289,000 |
| Dec 2024 | 0 | -129,728,000 | -124,697,000 | 188,662,000 | 51,416,000 | — | -100,012,000 |
| Dec 2023 | 0 | -104,315,000 | -96,015,000 | 164,939,000 | 38,458,000 | — | -94,180,000 |
| Dec 2022 | 8,094,000 | -99,274,000 | -85,981,000 | 260,252,000 | 48,586,000 | — | -97,977,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.75
Max Pain — expiry 2026-09-18
max pain strike: $9.00 · spot: $9.67 · call oi: 1,132 · put oi: 323
Expected Move to 2026-09-18:
±$2.03
(20.94%) —
implied range
$7.65 –
$11.70
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | $984.03M | $12.86 | — |
| DBVT | DBV Technologies S.A. | $888.64M | $14.14 | — |
| SANA | Sana Biotechnology, Inc. | $1.13B | $3.78 | — |
| FDMT | 4D Molecular Therapeutics, Inc. | $850.21M | $15.39 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.18B | $13.77 | — |
News headlines (Yahoo Finance, 1h cache)
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?
2026-07-02 03:28 · Yahoo
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
2026-06-02 11:00 · Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-01 20:05 · Yahoo
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-12 20:08 · Yahoo
Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
2026-05-07 12:00 · Yahoo
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
2026-04-30 12:00 · Yahoo
Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy
2026-04-28 12:00 · Yahoo
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-04-07 12:00 · Yahoo
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-06 20:08 · Yahoo
Sarepta's Elevidys Showing Signs of Stabilization as siRNA Pipeline Gains Importance, RBC Says
2026-06-18 15:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.